



- (51) **International Patent Classification:**
A23L 1/305 (2006.01) *A23L 1/29* (2006.01)
- (21) **International Application Number:**
PCT/NL2014/050315
- (22) **International Filing Date:**
19 May 2014 (19.05.2014)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (71) **Applicant:** N.V. NUTRICIA [NL/NL]; Eerste Stationsstraat 186, NL-2712 HM Zoetermeer (NL).
- (72) **Inventors:** VAN DER BEEK, Eline Marleen; Uppsalalaan 12, NL-3584 CT Utrecht (NL). ABRAHAMSE-BERKEVELD, Marieke; Uppsalalaan 12, NL-3584 CT Utrecht (NL). VAN GOUDOEVER, Johannes Bernard; Uppsalalaan 12, NL-3584 CT Utrecht (NL). TELLER, Inga Christiane; Uppsalalaan 12, NL-3584 CT Utrecht (NL).
- (74) **Agent:** NEDERLANDSCH OCTROOIBUREAU; Anna van Buerenplein 21 A, 2595 DA The Hague (NL).
- (81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM,

AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

- (84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) **Title:** ENTERAL FORMULATIONS FOR PRETERM INFANTS COMPRISING OPTIMISED PHENYLALANINE INTAKE LEVELS

(57) **Abstract:** The present invention relates to enteral formulations for preterm infants (e.g., preterm formulas and human milk fortifiers) containing optimised intake levels of phenylalanine for the preterm infants. It particularly relates to a preterm formulation comprising a proteinaceous composition, wherein the preterm formulation (a) comprises 2.0-2.29 g phenylalanine per 100 g protein; (b) comprises 64.00-82.29 mg phenylalanine per 100 kcal; and/or (c) provides, or is formulated to provide phenylalanine in an amount of 80-96 mg / kg body weight per day.



WO 2015/178762 A1

ENTERAL FORMULATIONS FOR PRETERM INFANTS COMPRISING OPTIMISED PHENYLALANINE INTAKE LEVELS

FIELD

5 The present invention relates to the determination of optimal intake levels of phenylalanine for preterm infants, and to enteral formulations (*e.g.*, preterm formulas and human milk fortifiers) that achieve these optimal intake levels. The present invention also relates to the administration of these enteral formulations to preterm infants, particularly in order to promote, assist or achieve balanced growth and/or
10 development of the preterm infants.

BACKGROUND

Protein accretion is a crucial part of growth, especially during foetal life and early infancy, which explains at least in part the higher needs for protein of preterm infants.

15 The protein composition in preterm human milk (*i.e.*, human milk from a mother who has delivered a preterm infant) differs from term human milk (Zhang 2013) to compensate at least in part for these higher needs. However, although this transitory compensation mechanism takes place in preterm milk composition, the high energy, protein, mineral, and vitamin requirements of a preterm infant may not always be met
20 in the preterm human milk. But as human milk is the preferred feeding for preterm infants, required for healthy gut development, prevention of infection and reducing the risk of potentially fatal diseases such as necrotising enterocolitis, fortification of preterm milk has been recommended by ESPGHAN (Agostoni, 2010) to provide all the benefits of human milk and also meet the additional nutritional support required by
25 these vulnerable infants. Only when maternal or donor milk is not available for fortification, a preterm formula particularly composed to meet requirements of preterm infants can be considered (Agostoni, 2010). Preterm formulas specifically designed for preterm infants thus contain higher levels of protein compared to infant formulas for term infants so that the increased protein requirements of these fragile infants can be
30 met.

Although the protein needs of preterm infants has been intensively studied, thus leading to many publications and ESPGHAN guidelines on the protein intake levels in preterm formulas, there has not been so much attention paid to the quality of the protein

needed by preterm infants. The protein component of enteral formulations for preterm infants (*e.g.*, preterm formulas, human milk fortifiers, other protein supplements), like all infant formulas, is made from non-human milk sources. Typically bovine milk is used, but other animal milk sources including caprine (goat's) milk may be used, or
5 non-animal protein sources such as vegetable (*e.g.* soy) protein may be used. None of these sources match exactly the protein quality of human milk.

Protein quality is largely determined by the amino acid composition of protein, as amino acids are the building blocks of protein. One of the amino acids, phenylalanine, plays a number of important metabolic roles. This essential aromatic amino acid serves
10 as a precursor via phenylalanine hydroxylation to tyrosine, the monoamine signalling molecules dopamine, norepinephrine, and epinephrine, and the skin pigment melanin.

Symptoms of phenylalanine deficiency include confusion, lack of energy, depression, decreased alertness, memory problems, and lack of appetite. On the other hand, phenylalanine in large quantities can interfere with the production of serotonin, a
15 neurotransmitter derived from tryptophan and involved in gut motility regulation that has been linked to feelings of well-being and happiness in adults. Further, the rare metabolic disorder phenylketonuria (PKU) occurs when a specific enzyme to use phenylalanine is missing. This causes a build-up of high phenylalanine concentrations that if not treated before 3 weeks of age can cause severe, irreversible mental and
20 intellectual disability.

It is therefore important to find the right balance of phenylalanine in a young infant's diet, especially in the preterm infant where additional risks for healthy and normal growth and/or development exist.

25 **SUMMARY**

The present inventors researched phenylalanine uptake and protein synthesis in preterm infants and discovered that a preterm infant's requirements of phenylalanine do not appear to be in line with existing preterm formulations, including preterm formulas and human milk fortifiers.

30 More specifically, the inventors have found that a preterm infant's requirements of phenylalanine are lower than the amounts currently recommended for and applied in preterm formulas and human milk fortifiers. The inventors established the phenylalanine requirement of preterm infants to be 80 mg/kg/day, which is 80-96

mg/kg per day with a 20% variation permitted (e.g. to compensate for product-allowed variation). The requirement of 80 mg/kg per day was subsequently determined to be about 2.0-2.29 g / 100 g (protein) and 64.00-82.29 mg / 100 kcal. In the context of human milk fortifiers, these levels correspond to 0-11.52 mg / 100 kcal or 0-9.72 mg / g (protein). These findings suggest that the phenylalanine levels required by preterm infants are considerably (and unexpectedly) lower than those found in existing preterm formulations such as preterm formulas and human milk fortifiers. For instance, in cow's milk-based preterm formulas, phenylalanine levels have been reported to vary between 3.54-4.53 g (phenylalanine) / 100 g protein (Picaud, 2001; Moro, 1999; Darling, 1999; Szajewska, 2001) or 91.64-118.25 mg (phenylalanine) / 100 kcal (Picaud, 2001; Moro, 1999; Darling, 1999; Szajewska, 2001).

Thus based on the inventors' findings, it is proposed that preterm formulations, especially preterm formulas and human milk fortifiers, can be produced with reduced phenylalanine concentrations.

Furthermore, based on the competition between amino acids and need for bioavailability of amino acids in infants (especially in preterm infants), it is proposed that such preterm formulas can be produced with an optimised amino acid profile. For example, a preterm formula with a lowered phenylalanine concentration will require a relative increase of other amino acids in the formula in order to maintain a desired total protein intake level for preterm infants between 3.5-4.0 g protein / kg / day (Agostoni, 2010). It is proposed that such preterm formulas can better meet the needs of preterm infants, thus promoting better growth and/or development in this vulnerable target group.

Thus, according to one aspect of the present invention, we provide a proteinaceous composition comprising an optimised phenylalanine concentration. The proteinaceous composition may comprise intact proteins, hydrolysed proteins, protein fractions, free amino acids and/or a combination thereof. The proteinaceous composition is suitably intended to be part of a preterm formulation, and is suitably intended for preterm infant. Based on the inventors' findings as outlined herein, in some embodiments the proteinaceous composition comprises 2.0-2.29 g phenylalanine per 100 g protein. Suitably, the proteinaceous composition comprises 2.0-2.25 g, more suitably 2.05-2.20 g, more suitably 2.05-2.15 g, most suitably 2.1-2.15 g phenylalanine per 100 g protein.

There is provided, according to another aspect of the present invention a preterm formula comprising the proteinaceous composition as defined above. In addition or alternatively, there is provided a preterm formula comprising 64.00-82.29 mg phenylalanine per 100 kcal and/or providing, or being formulated to provide

5 phenylalanine in a concentration of 80-96 mg per kg body weight per day (mg/kg body weight/day). Suitably, the formula comprises 64.00-82.29 mg phenylalanine per 100 kcal and provides, or is formulated to provide, phenylalanine in an amount of 80-96 mg per kg body weight per day.

In one aspect of the invention, there is provided a preterm formula comprising a

10 proteinaceous composition, wherein the formula:

- a) comprises 2.0-2.29 phenylalanine per 100 g protein;
- b) comprises 64.00-82.29 mg phenylalanine per 100 kcal; and/or
- c) provides, or is formulated to provide phenylalanine in an amount of 80-96 mg per kg body weight per day.

15 In a further aspect of the invention, there is provided a preterm formulation comprising human milk and a human milk fortifier, wherein the preterm formulation:

- a) comprises 2.0-2.29 phenylalanine per 100 g protein;
 - b) comprises 64.00-82.29 mg phenylalanine per 100 kcal; and/or
 - c) provides, or is formulated to provide phenylalanine in an amount of 80-96
- 20 mg per kg body weight per day.

In yet another aspect of the invention, there is provided a human milk fortifier comprising a proteinaceous composition, wherein the human milk fortifier:

- a) comprises 0-11.52 mg phenylalanine per 100 kcal;
- b) comprises 0-9.72 mg phenylalanine per g protein; and/or
- 25 c) provides, or is formulated to provide phenylalanine in an amount of 80-96 mg per kg body weight per day.

For the human milk fortifier, "formulated to provide phenylalanine in an amount of 80-96 mg per kg body weight per day" should suitably be understood to imply that human milk and milk fortifier together provide phenylalanine in an amount of 80-96 mg per kg

30 body weight per day.

According to another aspect of the present invention, there is provided a preterm formulation (*e.g.*, preterm formula or human milk fortifier) as defined herein for use in promoting, assisting or achieving balanced growth or development in a preterm infant.

Also provided is the use of a composition in the manufacture of a preterm formulation (*e.g.*, preterm formula or human milk fortifier) as defined herein for promoting, assisting or achieving balanced growth or development in a preterm infant. Also provided is a method for promoting, assisting or achieving balanced growth or development in a preterm infant, wherein the method comprises administering to the preterm infant a preterm formulation (*e.g.*, preterm formula or human milk fortifier) as defined herein.

As another aspect of the present invention, there is provided a preterm formulation (*e.g.*, preterm formula or human milk fortifier) as defined herein for use in preventing or reducing the risk of unbalanced growth or development in a preterm infant. Also provided is the use of a composition in the manufacture of a preterm formulation (*e.g.*, preterm formula or human milk fortifier) as defined herein for use in preventing or reducing the risk of unbalanced growth or development in a preterm infant. Also provided is a method for preventing or reducing the risk of unbalanced growth or development in a preterm infant, wherein the method comprises administering to the infant a preterm formulation (*e.g.*, preterm formula or human milk fortifier) as defined herein. The formula is suitably a preterm formula comprising the proteinaceous composition as described in the context of the invention or a preterm formulation comprising human milk and a human milk fortifier as described herein.

As used herein, the term “growth or development” may refer to growth and development of the brain of a preterm infant and/or the cognitive function of the infant as discussed further below, and/or to growth and development of the body of a preterm infant and/or the infant’s body composition, also as discussed further below.

The proteinaceous compositions and preterm formulations (including preterm formulas and human milk fortifiers) of the various aspects of the invention are discussed in more detail further below.

Another aspect of the present invention pertains to a method for the manufacture of a preterm formulation, the method comprising admixing:

- a) human breast milk; and
- b) a human milk fortifier composition comprising a proteinaceous composition, wherein the human milk fortifier composition:
 - a) comprises 0-9.72 phenylalanine per 100 g protein;
 - b) comprises 0-11.52 mg phenylalanine per 100 kcal; and/or

- c) provides, or is formulated to provide phenylalanine in an amount of 80-96 mg per kg body weight per day.

For the human milk fortifier, “formulated to provide phenylalanine in an amount of 80-96 mg per kg body weight per day” should suitably be understood to imply that human milk and milk fortifier together provide phenylalanine in an amount of 80-96 mg per kg body weight per day.

In yet another aspect of the present invention, there is provided a method for providing nutrition to a preterm infant, the method comprising administering to the infant a proteinaceous composition or a preterm formulation (*e.g.* preterm formula or human milk fortifier or formulation comprising human milk and human milk fortifier) of the present invention. The method may suitably comprise the steps a) admixing i) a nutritionally or pharmaceutically acceptable liquid (*e.g.*, water); and ii) a dry composition, wherein the dry composition comprises the proteinaceous composition or preterm formulation of the present invention, and step b) administering the liquid composition obtained in step a) to a preterm infant. In other embodiments, the method may suitably comprise admixing i) human milk; and ii) the human milk fortifier of the present invention, and step b) administering the liquid composition obtained in step a) to a preterm infant.

20 **BRIEF DESCRIPTION OF THE FIGURES**

Figure 1 shows an example of a graph plotted by the IAAO method for a test amino acid as described in the introduction for Example 1.

Figure 2 shows the rates of release of $^{13}\text{CO}_2$ in the breath of 16 preterm infants (F^{13}CO_2) at 24 different phenylalanine intakes as described in Example 1. Using a biphasic linear regression crossover model, the mean breakpoint was estimated to be 80 $\text{mg} \cdot \text{kg}^{-1} \cdot \text{d}^{-1}$ ($P < 0.01$, $r^2 = 0.54$).

LIST OF PREFERRED EMBODIMENTS

1. A preterm formulation comprising a proteinaceous composition, wherein the preterm formulation:
 - a) comprises 2.0-2.29 g phenylalanine per 100 g protein;
 - b) comprises 64.00-82.29 mg phenylalanine per 100 kcal; and/or

- c) provides, or is formulated to provide phenylalanine in an amount of 80-96 mg / kg body weight per day.
- 2. A preterm formulation according to embodiment 1, comprising a preterm formula.
- 3. A preterm formulation according to embodiment 1, comprising human milk and a human milk fortifier.
- 5 4. A preterm formulation comprising a human milk fortifier comprising a proteinaceous composition, wherein the human milk fortifier:
 - a) comprises 0-11.52 mg phenylalanine per 100 kcal;
 - b) comprises 0-9.72 mg phenylalanine per g protein; and/or
 - 10 c) provides, or is formulated to provide phenylalanine in an amount of 80-96 mg per kg body weight per day.
- 5. Use of a composition in the manufacture of a preterm formulation, wherein the preterm formulation is a preterm formulation according to any one of embodiments 1-4.
- 15 6. Use of a composition in the manufacture of a preterm formulation for promoting, assisting or achieving balanced growth or development in a preterm infant and/or for preventing or reducing the risk of unbalanced growth or development in a preterm infant, wherein the preterm formulation is a preterm formulation according to any one of embodiments 1-4.
- 20 7. Use of a composition in the manufacture of a preterm formulation for promoting, assisting or achieving balanced growth or development of the brain of a preterm infant and/or the cognitive function of a preterm infant, wherein the preterm formulation is a preterm formulation according to any one of embodiments 1-4.
- 8. Use of a composition in the manufacture of a preterm formulation for promoting, assisting or achieving balanced growth or development of the body of a preterm infant and/or the preterm infant's body composition, wherein the preterm formulation is a formula according to any one of embodiments 1-4.
- 25 9. Method for providing nutrition to a preterm infant; and/or for promoting, assisting or achieving balanced growth or development in a preterm infant and/or for preventing or reducing the risk of unbalanced growth or development in a preterm infant, said method comprising administering a preterm formulation according to any one of embodiments 1-4 to said preterm infant.
- 30

10. Method of embodiment 9, for promoting, assisting or achieving balanced growth or development of the brain of the infant and/or the cognitive function of the preterm infant.
11. Method of embodiment 9, for promoting, assisting or achieving balanced growth or development of the body of a preterm infant and/or the preterm infant's body composition.
12. A method for the manufacture of a preterm formulation, the method comprising admixing:
 - i. human breast milk; and
 - 10 ii. a human milk fortifier composition comprising a proteinaceous composition, wherein the human milk fortifier composition:
 - a) comprises 0-9.72 phenylalanine per 100 g protein;
 - b) comprises 0-11.52 mg phenylalanine per 100 kcal; and/or
 - c) provides, or is formulated to provide phenylalanine in an amount of 80-15 96 mg per kg body weight per day.
13. A proteinaceous composition comprising 2.0-2.29 g phenylalanine per 100 g protein.
14. Preterm formulation for use in providing nutrition to a preterm infant; and/or for use in promoting, assisting or achieving balanced growth or development in a preterm infant and/or for use in preventing or reducing the risk of unbalanced growth or development in a preterm infant, comprising administering a preterm formulation according to any one of embodiments 1-4 to said preterm infant.
15. Preterm formulation for use according to embodiment 14, for use in promoting, assisting or achieving balanced growth or development of the brain of the infant and/or the cognitive function of the preterm infant.
16. Preterm formulation for use according to embodiment 14, for use in promoting, assisting or achieving balanced growth or development of the body of a preterm infant and/or the preterm infant's body composition.
- 30 The embodiments will be outlined here below.

DETAILED DESCRIPTION OF THE INVENTION**Proteinaceous Compositions**

The present invention is based on the inventors' discovery of the requirements of preterm infants for phenylalanine by actual measurements of requirement intake levels in formula-fed preterm infants, and the subsequent determination of those intake levels in the context of product (*e.g.*, concentrations in preterm formulations such as preterm formulas and human milk fortifiers).

Interestingly, it is noted that the intake requirement of phenylalanine (or phenylalanine concentrations) deviates from the concentrations used in commercially available preterm formulas. For instance, in cow's milk-based preterm formulas, phenylalanine concentrations have been reported to vary between 3.54-4.53 g (phenylalanine) / 100 g protein (Picaud, 2001; Moro, 1999; Darling, 1999; Szajewska, 2001) or 91.64-118.25 mg (phenylalanine) / 100 kcal (Picaud, 2001; Moro, 1999; Darling, 1999; Szajewska, 2001). By contrast, the inventors surprisingly discovered that the intake level of phenylalanine required for protein synthesis (and therefore for growth and development) in preterm infants are met at a lower concentration. These results also suggest that preterm formulas based on this discovery that maintain the same protein levels as existing preterm formulas, must have an altered ratio between phenylalanine and other amino acids, especially large neutral amino acids (valine, leucine, isoleucine, tryptophan, tyrosine and methionine). These insights could mean that by reducing phenylalanine concentrations relative to the other large neutral amino acids, the large neutral amino acids involved in protein accretion will have a better bioavailability due to less transporter competition. As a result, the lower ratio of phenylalanine to large neutral amino acids may induce a higher growth in lean body mass (muscle accretion) as well as brain development by increased cerebral protein synthesis.

Furthermore, too high concentrations of phenylalanine might interfere with the development of balanced growth and/or body composition, including lean body mass, by influencing the uptake of large neutral amino acids. Thus, using the new phenylalanine concentrations and optionally a lower ratio of phenylalanine to large neutral amino acids in proteinaceous compositions and preterm formulations (*e.g.*, preterm formulas or human milk fortifiers) proposed herein, may allow for

compositions that promote balanced growth and/or development, as further described herein.

The invention thus pertains to a proteinaceous composition comprising 2.0-2.29 g phenylalanine per 100 g protein, suitably 2.0-2.25 g phenylalanine per 100 g protein, more suitably 2.05-2.20 g phenylalanine per 100 g protein, even more suitably 2.05-2.15 g phenylalanine per 100 g protein, most suitably 2.10-2.15 g phenylalanine per 100 g protein.

The proteinaceous composition may comprise intact proteins, hydrolysed proteins, protein fractions, free amino acids and/or a combination thereof. Where hydrolysed proteins are used, they may comprise partially and/or extensively hydrolysed proteins.

The proteinaceous composition of any aspect of the present invention may comprise a ratio of essential amino acids to non-essential amino acids of 40-60 : 40-60, suitably 45-55 : 45-55, even more suitably 48-52 : 48-52.

The proteinaceous composition is suitably intended to be part of a preterm formulation, especially a preterm formula or a human milk fortifier, and is suitably intended for a preterm infant. Therefore, throughout this specification, the term “preterm infant” (or “preterm”) means an infant born before completion of 37 weeks of gestation. Suitably, the term “preterm infant” refers to an infant weighing >1000 g at birth, most suitably the term “preterm infant” refers to an infant weighing 1000-1800 g at birth.

Preterm Formulations

The term “preterm formulation” as used herein is intended to encompass all formulations (e.g. formulas and fortifiers) intended for a preterm infant. Exemplary preterm formulations include preterm formulas and also human milk fortifiers as herein defined (e.g., those which are intended to be admixed with human milk before administration to a preterm infant), and also a composition comprising human milk and a human milk fortifier.

Accordingly, an aspect of the present invention provides a preterm formula comprising a proteinaceous composition, wherein the formula:

- a) comprises 2.0-2.29 g phenylalanine per 100 g protein;
- b) comprises 64.00-82.29 mg phenylalanine per 100 kcal; and/or

- c) provides, or is formulated to provide phenylalanine concentrations of 80-96 mg / kg /day.

In an exemplary embodiment, the formula complies with at least (a). Suitably, the formula complies with at least both (a) and (b), with at least both (a) and (c), or with at least both (a), (b) and (c). In another embodiment, the formula complies with at least (b), suitably complies with at least both (b) and (c).

Suitably, the formula comprises 2.0-2.25 g phenylalanine per 100 g protein, more suitably 2.05-2.20 g, even more suitably 2.05-2.15 g, most suitably 2.10-2.15 g phenylalanine per 100 g protein.

Suitably, the formula comprises 65-81 mg phenylalanine per 100 kcal, more suitably 67-79 mg phenylalanine per 100 kcal, even more suitably 69-77 mg phenylalanine per 100 kcal, most suitably 71-75 mg phenylalanine per 100 kcal.

Suitably, the formula provides, or is formulated to provide phenylalanine in an amount of 82-95 mg / kg body weight / day, more suitably in an amount of 83-92 mg / kg body weight / day, even more suitably in an amount of 84-90 mg / kg body weight / day, most suitably in an amount of 85-88 mg / kg body weight / day.

Another aspect of the invention provides a preterm formulation comprising human milk and a human milk fortifier, wherein the preterm formulation:

- a) comprises 2.0-2.29 phenylalanine per 100 g protein;
b) comprises 64.00-82.29 mg phenylalanine per 100 kcal; and/or
c) provides, or is formulated to provide phenylalanine in an amount of 80-96 mg per kg body weight per day.

In an exemplary embodiment, the preterm formulation complies with at least (a). Suitably, the preterm formulation complies with at least both (a) and (b), with at least both (a) and (c), or with at least both (a), (b) and (c). In another embodiment, the preterm formulation complies with at least (b), suitably complies with at least both (b) and (c).

Suitably, the preterm formulation comprises 2.0-2.25 g, more suitably 2.05-2.20 g, even more suitably 2.05-2.15 g, most suitably 2.10-2.15 g phenylalanine per 100 g protein.

Suitably, the preterm formulation comprises 65-81 mg phenylalanine per 100 kcal, more suitably 67-79 mg phenylalanine per 100 kcal, even more suitably 69-77 mg phenylalanine per 100 kcal, most suitably 71-75 mg phenylalanine per 100 kcal.

Suitably, the preterm formulation provides, or is formulated to provide phenylalanine in an amount of 82-95 mg / kg body weight / day, more suitably in an amount of 83-92 mg / kg body weight / day, even more suitably in an amount of 84-90 mg / kg body weight / day, most suitably in an amount of 85-88 mg / kg body weight / day.

In yet another aspect of the invention, there is provided a human milk fortifier comprising a proteinaceous composition, wherein the human milk fortifier:

- a) comprises 0-11.52 mg phenylalanine per 100 kcal;
- b) comprises 0-9.72 mg phenylalanine per g protein; and/or
- 10 c) provides, or is formulated to provide phenylalanine in an amount of 80-96 mg per kg body weight per day.

In an exemplary embodiment, the human milk fortifier complies with at least (a). Suitably, the human milk fortifier complies with at least both (a) and (b), with at least both (a) and (c), or with at least both (a), (b) and (c). In another embodiment, the human milk fortifier complies with at least (b), suitably complies with at least both (b) and (c).

Suitably, the human milk fortifier comprises 1-11 mg phenylalanine per 100 kcal, more suitably 2-10 mg phenylalanine per 100 kcal, more suitably 3-9 mg phenylalanine per 100 kcal, even more suitably 4-8 mg phenylalanine per 100 kcal, most suitably 5-7 mg phenylalanine per 100 kcal.

Suitably, the human milk fortifier comprises 1-9 mg phenylalanine per g protein, more suitably 2-8 mg phenylalanine per g protein, even more suitably 3-7 mg phenylalanine per g protein, most suitably 4-6 mg phenylalanine per g protein.

Suitably, the human milk fortifier provides, or is formulated to provide phenylalanine in an amount of 82-95 mg / kg body weight / day, more suitably in an amount of 83-92 mg / kg body weight / day, even more suitably in an amount of 84-90 mg / kg body weight / day, most suitably in an amount of 85-88 mg / kg body weight / day.

The proteinaceous composition or preterm formulation of any aspect of the present invention may comprise a ratio of essential amino acids to non-essential amino acids of 40-60 : 40-60, suitably 45-55 : 45-55, even more suitably 48-52 : 48-52.

The proteinaceous composition or preterm formulation (*e.g.* preterm formula or composition comprising human milk and a human milk fortifier) of any aspect of the

present invention may be intended as a complete nutrition for infants. Suitably, the preterm formulation (*e.g.*, preterm formula or human milk fortifier or composition comprising human milk and a human milk fortifier) of any aspect of the present invention is intended for a preterm infant. Suitably, the preterm formulation (*e.g.*,
5 preterm formula or human milk fortifier or composition comprising human milk and a human milk fortifier) of any aspect of the present invention is intended for a human preterm infant.

The proteinaceous composition or preterm formulation of the invention is typically intended for preterm infants from birth to hospital discharge and/or upon discretion of
10 the health care professional.

The proteinaceous composition or preterm formulation (*e.g.*, preterm formula or human milk fortifier or composition comprising human milk and a human milk fortifier) of the present invention may comprise an enteral composition, *i.e.*, any composition that is enterally administered, such as orally. As used in this document, the
15 term “enteral” is intended to refer to the delivery directly into the gastrointestinal tract of a subject (*e.g.*, orally or via a tube, catheter or stoma), as opposed to a direct delivery into the blood stream (parenteral feeding).

The proteinaceous composition or preterm formulation (*e.g.*, preterm formula, human milk fortifier, or composition comprising human milk and said human milk
20 fortifier) of the present invention may be formulated for administration in a liquid form. In some embodiments, the preterm formulation may comprise a powder suitable for making a liquid composition after reconstitution with an aqueous solution, such as with water or human milk. The preterm formulation may be made up as a packaged powder composition wherein the package is provided with instructions to admix the powder
25 with a suitable amount of aqueous solution, thereby resulting in a liquid composition. In some other embodiments, the preterm formulation may comprise a ready-to-use liquid food (*e.g.*, is in a ready-to-feed liquid form). A packed ready-to-use liquid food may involve fewer steps for preparation than a powder to be reconstituted and hence may involve a reduced chance on contamination by harmful micro-organisms.

(i) Preterm Formulas

Preterm formulas are employed with preterm infants when maternal milk or donor milk (optionally with fortification) is not available. The present invention provides preterm formulas as herein defined.

- 5 The protein intake recommendation of preterm infants with a birth weight of less than 1000 g is $4.0\text{-}4.5 \text{ g}\cdot\text{kg}^{-1}\text{d}^{-1}$. Accordingly, the preterm formula of the present invention may comprise a protein concentration corresponding to a protein intake of $4.0\text{-}4.5 \text{ g}\cdot\text{kg}^{-1}\text{d}^{-1}$, suitably $4.1\text{-}4.5 \text{ g}\cdot\text{kg}^{-1}\text{d}^{-1}$, more suitably $4.2\text{-}4.4 \text{ g}\cdot\text{kg}^{-1}\text{d}^{-1}$.

- 10 The preterm formula of the present invention may comprise 3.2-4.1 g protein per 100 kcal, suitably 3.6-4.1 g protein per 100 kcal, more suitably 3.7-4.1 g protein per 100 kcal. Suitably, such preterm formula is intended for a preterm infant weighing < 1000 g at birth.

- 15 The protein intake recommendation of preterm infants with a birth weight between 1000-1800 g is $3.5\text{-}4.0 \text{ g}\cdot\text{kg}^{-1}\text{d}^{-1}$. Accordingly, the preterm formula of the present invention may comprise a protein concentration corresponding to a protein intake of $3.5\text{-}4.0 \text{ g}\cdot\text{kg}^{-1}\text{d}^{-1}$, suitably $3.6\text{-}4.0 \text{ g}\cdot\text{kg}^{-1}\text{d}^{-1}$, more suitably $3.7\text{-}3.9 \text{ g}\cdot\text{kg}^{-1}\text{d}^{-1}$.

- 20 In other embodiments, the preterm formula of the present invention may comprise 3.2-3.6 g protein per 100 kcal, suitably 3.3-3.6 g protein per 100 kcal, more suitably 3.4-3.5 g protein per 100 kcal. Suitably, such preterm formula is intended for a preterm infant weighing 1000-1800 g at birth.

- 25 The preterm formula of the present invention may further comprise a lipid, a carbohydrate, a vitamin and/or a mineral. In some embodiments, the preterm formula may comprise between 5 and 50 en% lipid, between 5 and 50 en% protein, between 15 and 90 en% carbohydrate. Suitably, the preterm formula may comprise between 35 and 50 en% lipid, between 7.5 and 18 en% protein and between 35 and 80 en% carbohydrate (en% is short for energy percentage and represents the relative amount each constituent contributes to the total caloric value of the preparation). The preterm formula may provide a carbohydrate intake of 10-14 g / 100 kcal, suitably 10.5-12 g / 100 kcal.

- 30 The preterm formula may further comprise a non-digestible oligosaccharide. Suitably, the non-digestible oligosaccharide may be selected from the group consisting of galacto-oligosaccharides, fructo-oligosaccharides and acidic oligosaccharides. Such oligosaccharides are well known to those skilled in the art.

The preterm formula may further comprise a polyunsaturated fatty acid (PUFA). Suitably, the PUFA may be selected from the group consisting of alpha-linolenic acid (ALA), linoleic acid (LA), eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), arachidonic acid (ARA), and docosapentaenoic acid (DPA). Suitably, the PUFA may be a long chain polyunsaturated fatty acid (LCPUFA) (*e.g.*, EPA, DHA, ARA, DPA). Such PUFAs are well known to those skilled in the art.

The preterm formula may further comprise a probiotic. Suitable probiotics are well known to those skilled in the art. The probiotic may comprise a lactic acid producing bacterium. The probiotic may comprise a *Lactobacillus* species. The probiotic may comprise a *Lactobacillus rhamnosus* strain (including *L. rhamnosus* GG, also referred to as “LGG”), a *Lactobacillus salivarius* strain, a *Lactobacillus casei* strain, a *Lactobacillus paracasei* strain (including *L. paracasei* F19), a *Lactobacillus acidophilus* strain, a *Lactobacillus reuteri* strain, and/or a *Lactobacillus helveticus* strain. The probiotic may comprise a *Bifidobacterium* species. The probiotic may comprise a *Bifidobacterium longum* strain, a *Bifidobacterium infantis* strain, a *Bifidobacterium breve* strain (including *B. breve* M-16V and *B. breve* BbC50), a *Bifidobacterium animalis* strain (including *B. animalis* subsp. *lactis*, including subsp. *lactis* BB-12 and subsp. *lactis* Bi-07), and/or a *Bifidobacterium bifidum* strain. In some embodiments, the probiotic may be viable or non-viable. As used herein, the term “viable”, refers to live microorganisms. The term “non-viable” or “non-viable probiotic” means non-living probiotic microorganisms, their cellular components and metabolites thereof. Such non-viable probiotics may have been heat-killed or otherwise inactivated but retain the ability to favourably influence the health of the host. The probiotics may be naturally-occurring, synthetic or developed through the genetic manipulation of organisms, whether such new source is now known or later developed. Suitably, the preterm formula does not comprise *Saccharomyces cerevisiae*.

The preterm formula may comprise a fermented or a non-fermented composition. Fermentation by micro-organisms results in a lowering of the pH. As a non-fermented composition, the preterm formula may have a pH above 5.5, such as 6.0, such as 6.5 (for example, in order to reduce damage to teeth). The pH may suitably be between 6 and 8.

The preterm formula may be formulated to provide an energy intake of 110-135 kcal / kg / day, or 72-200 kcal/100 ml, suitably 76-120 kcal/100 ml, more suitably 77-

100 kcal/100 ml, even more suitably 78-90 kcal/100 ml, most suitably 79-83 kcal/100 ml.

The preterm formula may have a long shelf life. For example, it may be shelf stable at ambient temperature for at least 6 months, such as at least 12 months, where it is in a liquid, ready-to-feed form or where it is in a powder form.

Suitably, the preterm formulas of the present invention do not comprise or consist of human breast milk.

(ii) Human Milk Fortifiers

Fortification of human milk intended for preterm infants is done in order to provide all the benefits of human milk and also meet the additional nutritional support required by this vulnerable class of infants. The present invention provides human milk fortifiers and compositions comprising a combination of human milk and a human milk fortifier (HMF) as herein defined.

Human milk fortifiers are usually present as dose units which can be added to the human milk, mixed and subsequently the fortified human milk is administered to the preterm infant. This administration is enterally and may be orally via a bottle with a teat or by tube feeding. Preferably the dose units are sachets comprising 0.5-10 g based on dry weight, more preferably 1 – 8 g, even more preferably 2-4 g. Preferably the human milk fortifier is a reconstitutable powder. A reconstitutable powder is a powder which can be dissolved in an aqueous liquid. Powdered human milk formulae have the advantage that they minimize the volume displacement of human milk. Preferably the HMF is administered in a quantity of 0.1 to 20 g dry weight per day, more preferably 0.5 to 10 g dry weight per day. In one embodiment the human milk fortifier is present in the form of a concentrated liquid. Use of concentrated liquid human milk fortifiers may reduce the risk of microbial contamination associated with the preparation of an infant feeding.

The HMF suitably comprises at least 20 % protein based on total calories, more suitably at least 25 %, even more suitably at least 30 % based on total calories. Suitably the HMF comprises less than 75 % protein based on total calories, more suitably less than 60 %. Suitably the HMF comprises at least 15 wt.% protein based on dry weight, more suitably at least 20 wt.%, even more suitably at least 30 wt.%. Suitably the HMF

does not comprise more than 75 wt.% protein based on dry weight, more preferably not more than 50 wt.%.

In one embodiment, the HMF suitably comprises at least 5 % fat based on total calories, more suitably at least 15 %, even more preferably at least 25 % based on total calories. Preferably the HMF does not comprise more than 75 % fat based on total calories, even more preferably not more than 50 % fat based on total calories. Preferably the HMF comprises at least 2 wt.% fat based on dry weight, more preferably at least 5 wt.%, even more preferably at least 10 wt.% based on dry weight of the composition. Preferably the HMF does not comprise more than 75 wt.% based on dry weight, more preferably not more than 50 wt.%, even more preferably not more than 30 wt.% based on dry weight. The HMF preferably comprises long chain polyunsaturated fatty acid (LC-PUFAs).

Preferably the human milk fortifier comprises besides the protein and fat component also digestible carbohydrates. The HMF preferably comprises at least 10 % digestible carbohydrates based on total calories, more preferably at least 20 %, even more preferably at least 30 % based on total calories. Preferably the HMF does not comprise more than 70 % digestible carbohydrates based on total calories, even more preferably not more than 50 % based on total calories. Preferably the HMF comprises at least 10 wt.% digestible carbohydrate based on dry weight, more preferably at least 20 wt.%, even more preferably at least 35 wt.% based on dry weight of the HMF. Preferably the HMF does not comprise more than 75 wt.% digestible carbohydrate based on dry weight, more preferably not more than 60 wt.%, even more preferably not more than 50 wt.% based on dry weight. Suitable sources of digestible carbohydrates are lactose and maltodextrin. Lactose advantageously resembles the carbohydrates source in human milk. Maltodextrin advantageously decreases the overall osmolarity of the HMF.

Preferably the HMF comprises vitamins, minerals and trace elements. The HMF preferably comprises vitamin D. Preferably vitamin D is present at a concentration of at least 15 µg per 100 g dry weight of HMF, more preferably at least 50 µg per 100 g, even more preferably at least 100 µg per 100 g dry weight. Preferably the HMF comprises less than 500 µg vitamin D per 100 g dry weight, more preferably less than 200 µg. The HMF preferably comprises calcium. Preferably calcium is present at a concentration of at least 0.5 g per 100 g dry weight of HMF, more preferably at least

0.7 g per 100 g, even more preferably at least 1.0 g per 100 g dry weight. Preferably the HMF comprises less than 5.0 g calcium per 100 g dry weight, more preferably less than 2.00 g.

5 A low osmolality of the HMF will advantageously not increase the osmolality of the human milk after fortification. A too high osmolality of the fortified human milk increases the risk on necrotizing enterocolitis (NEC). NEC is especially a problem in preterm infants. Therefore the present fortified human milk when fortified with the HMF preferably has an osmolality between 300 and 480 mOsm/kg.

10 The preterm formulations or compositions that comprise human milk and a human milk fortifier as herein defined may meet any of the requirements for preterm formulas as hereinabove defined.

Suitably, the preterm formulation or composition that comprises human milk and a human milk fortifier as herein defined comprises 2.0-2.29 g phenylalanine per 100 g protein, more suitably 2.0-2.25 g, even more suitably 2.05-2.20 g, yet even more
15 suitably 2.05-2.15 g, most suitably 2.10-2.15 g phenylalanine per 100 g protein.

Suitably, the preterm formulation or composition that comprises human milk and a human milk fortifier as herein defined comprises 64- 82.29 mg phenylalanine per 100 kcal, more suitably 65-81 mg phenylalanine per 100 kcal, even more suitably 67-79 mg phenylalanine per 100 kcal, yet even more suitably 69-77 mg phenylalanine per 100
20 kcal, most suitably 71-75 mg phenylalanine per 100 kcal.

Suitably, the preterm formulation or composition that comprises human milk and a human milk fortifier as herein defined provides phenylalanine in an amount of 80-96 mg / kg body weight / day, more suitably in an amount of 82-95 mg / kg body weight / day, even more suitably in an amount of 83-92 mg / kg body weight / day, yet even
25 more suitably in an amount of 84-90 mg / kg body weight / day, most suitably in an amount of 85-88 mg / kg body weight / day.

Protein Sources

30 The proteinaceous compositions or preterm formulations of the present invention may comprise an intact protein, a hydrolysed protein, a protein fraction, a free amino acid and/or a combination thereof, such that the proteinaceous composition or preterm formulation comprises the amino acid profile of any aspect of the present invention.

The term “an intact protein” as used herein refers to any form of intact protein, including but not limited to a protein concentrate and/or a protein isolate, as well as other forms of intact proteins.

The term “hydrolysed protein” as used herein refers to partially and/or extensively hydrolysed proteins. Suitably the proteinaceous composition of the present invention comprises a hydrolysed protein with a degree of hydrolysis of between 5% and 25%, more suitably between 7.5% and 21%, most suitably between 10% and 20%. The degree of hydrolysis is defined as the percentage of peptide bonds which have been broken by enzymatic hydrolysis, with 100% being the total potential peptide bonds present. A suitable method for preparing a protein hydrolysate is described in WO 2001/041581, the entire contents of which is incorporated herein by reference.

The proteinaceous composition or preterm formulation may comprise any suitable intact protein, hydrolysed protein, protein fraction, free amino acid and/or a combination thereof, which is selected ensuring that the phenylalanine concentration of the proteinaceous composition or preterm formulations as defined herein are met. For instance, as discussed elsewhere, the present inventors have demonstrated the desirability of lowering the concentrations of phenylalanine from those found in commercially available preterm formulations and/or for lowering the concentration of phenylalanine relative to that of the other large neutral amino acids.

In some embodiments, the proteinaceous composition or preterm formulation comprises an intact protein, and a free amino acid. In some embodiments, the proteinaceous composition or preterm formulation comprises a hydrolysed protein and/or a protein fraction, and a free amino acid. In some embodiments, the proteinaceous composition or preterm formulation comprises free amino acids. In some embodiments, the proteinaceous composition or preterm formulation consists essentially of or consists of free amino acids.

The proteinaceous composition or preterm formulation may comprise a non-human animal protein (such as milk proteins, including caseins and whey proteins, meat proteins and egg proteins), a non-animal protein, a dairy protein, a non-cow dairy protein, a non-dairy protein, a vegetable protein, an algal protein, a hydrolysate of any of these proteins, a fraction of any of these proteins, a free amino acid, and/or a combination of any of these amino acid sources.

Suitably, the proteinaceous composition or preterm formulation comprises at least 40%, 50%, 60%, 70%, 80%, 90%, or 95% (or any integer in-between) of amino acid sources comprising an intact protein, a hydrolysed protein, a protein fraction, such that the proteinaceous composition comprises less than 5%, 10%, 20%, 30%, 40%, 50%, or 60% (or any integer in-between) of a free amino acid. Most suitably, the proteinaceous composition or preterm formulation comprises at least 60% of amino acid sources comprising an intact protein, a hydrolysed protein, a protein fraction, such that the proteinaceous composition comprises 40% or less of a free amino acid.

Reference throughout this document (both specification and claims) is made to weight units (milligrams or grams) of amino acids. Where expressed per weight unit of protein (*e.g.*, per 100 g protein), it should be noted that this expression refers to the relative weight of the amino acid(s) in terms of the protein weight, where the protein weight means the weight of all protein matter.

Furthermore, where reference throughout this document (both specification and claims) is made to weight units (milligrams or grams) of amino acids, it should be noted that these units are protein equivalent weights of amino acids (*i.e.*, the weight of amino acid when present in a protein). Thus, where a free amino acid is employed in the present invention, the dehydration synthesis reactions which occur when a protein is formed from free amino acids must be taken into account. Accordingly, if a free amino acid is employed in the present invention, the weight of the free amino acid that is required is 17% higher than the protein equivalent weight (as expressed herein). Such calculations and conversions are well known to those skilled in the art.

Suitable amino acid sources for the proteinaceous composition or preterm formulation may include, but are not limited to, cow's milk protein, whey (including acid whey, sweet whey, and alpha-lactalbumin enriched whey), alpha-lactalbumin, beta-lactoglobulin, glycomacropeptide, casein (including beta-casein), skim milk, lactoferrin, colostrum, goat's milk protein, donkey's milk protein, buffalo milk protein, fish, chicken protein, pork protein, soy protein (including soy protein isolate), pea protein (including pea protein isolate), wheat protein, rice protein, rice bran, potato protein (including potato protein isolate), another plant protein, fractions of any of these proteins, hydrolysates of any of these proteins, and free amino acids (including amino acids isolated from an amino acid source and/or amino acids that have been

chemically or synthetically produced). Suitably, the proteinaceous composition and/or the preterm formulation of the present invention comprise glycomacropeptide.

The amino acid profile of the proteinaceous composition or preterm formulation of the present invention, as described herein, refers to one or more essential amino acids (or conditionally essential amino acids in some instances). It will be recognised by those skilled in the art that the proteinaceous composition or preterm formulation will also comprise non-essential amino acids. Suitably, the proteinaceous composition or preterm formulation of the present invention comprises a ratio of essential amino acids to non-essential amino acids of 40-60 : 40-60, suitably 45-55 : 45-55, even more suitably 48-52 : 48-52. This is in line with the typical ratio of essential amino acids in human milk and commercially available formulas, thus it is noted that the present invention does not contemplate a lowering of the essential amino acids relative to the non-essential amino acids.

15 Balanced growth and/or development

As described herein, the present inventors have developed optimised proteinaceous compositions and preterm formulations. The optimised phenylalanine concentrations (or ratio of phenylalanine to large neutral amino acids) in these proteinaceous compositions and preterm formulations is designed from the real preterm infants' requirements that were measured as described herein. Therefore, these concentrations meet the needs of preterm infants and thus promote balanced growth and/or development in a preterm infant, and/or prevent or reduce the risk of unbalanced growth and/or development in a preterm infant.

The term "balanced" as used in the phrase "balanced growth and/or development" is intended to refer to healthy or normal growth and/or development of a preterm infant. For example, the growth and/or development is not too low/little or too high/much ("unbalanced growth and/or development"). In preterm infants, this often means a steady increase in weight and/ or length and/or head circumference, and/or no growth faltering in any of these anthropometric parameters. Balanced growth and/or development as used herein may be with reference to published figures that define the (e.g., healthy or normal) growth and/or development of a preterm infant with reference to a population (geographic, demographic, ethnic, etc) within which the infant belongs, or with reference to the growth and/or development an unhealthy infant or group of

unhealthy infants, such as the Fenton Growth charts for preterm infants
(<http://www.ucalgary.ca/fenton/2013chart>).

The term “growth and/or development” as used herein may refer to growth and/or development of the brain of a preterm infant and/or the cognitive function of the infant,
5 as further defined below, and/or to growth and/or development of the body of a preterm infant and/or the infant’s body composition, also as further defined below.

Brain and Cognitive Function

Balanced growth and/or development may refer to the balanced growth and/or
10 development of the brain of a preterm infant and/or the cognitive function of the infant. This may refer to physical development of the brain such as increased brain size, neuron proliferation and apoptosis, synapsis formation, rearrangement and/or number of synaptic connection, as well as neurotransmitter activity and also head circumference. This may also refer to any brain function or behaviour observed in the
15 infant or later in the life of the infant, such as visual development, sensory perception, language, higher cognitive functions (such as logic) but also emotional control, habits, mood, appetite, sleep, memory, learning, and some social skills and behaviours of the infant. It may also refer to preventing or reducing the infant’s risk for developing a psychiatric disease in later life (*e.g.*, an affective disorder, depression, schizophrenia).

20 As described herein, the recommended intake determined for phenylalanine, an essential amino acid that is associated with brain function, was found to be different to those found in commercially available preterm formulas. Furthermore, it is believed that the ratio between phenylalanine and the other large neutral amino acids tryptophan, valine, leucine, isoleucine, tyrosine and methionine and is also significantly different to
25 the recommended ratio, wherein it has been stated that an altered ratio might have possible implications on brain development. It is therefore believed that preterm formulations that comprise the modified phenylalanine concentrations as herein defined advantageously promote, assist, or achieve balanced growth or development of brain and cognitive function in preterm infants.

30

Body Growth, Development and Composition

Balanced growth and/or development may refer to the balanced growth and/or development of the body of a preterm infant and/or the infant’s body composition. This

may refer to the height, weight, fat distribution (*e.g.*, visceral fat versus subcutaneous fat), or other parameter of the infant, such parameters being well known to those skilled in the art.

5 Administration

Provided herein is a method for providing nutrition to a preterm infant, the method comprising administering to the infant a proteinaceous composition or a preterm formulation (*e.g.* preterm formula or human milk fortifier or formulation comprising human milk and human milk fortifier) of the present invention. Suitably, the infant is a
10 human preterm infant as described above.

The method may suitably comprise the steps a) admixing i) a nutritionally or pharmaceutically acceptable liquid (*e.g.*, water); and ii) a dry composition, wherein the dry composition comprises the proteinaceous composition or preterm formulation of the present invention, and step b) administering the liquid composition obtained in step
15 a) to a preterm infant. In other embodiments, the method may suitably comprise admixing i) human milk; and ii) the human milk fortifier of the present invention, and step b) administering the liquid composition obtained in step a) to a preterm infant.

20 EXAMPLES

Example 1: Amino acid (phenylalanine) requirements in preterm infants

This example describes the determination of the requirements of the essential amino acid phenylalanine in preterm infants by way of the indicator amino acid
25 oxidation (IAAO) method, and the subsequent definition of the recommended ranges of dietary requirements for this essential amino acid.

These infants (n=16) all had a gestational age of ≤ 37 weeks, and a weight of ≤ 2500 on study day. They were clinically stable and exhibited a weight gain rate of $10 \text{ g} \cdot \text{kg}^{-1} \cdot \text{d}^{-1}$ in the preceding 3 days.

30

IAAO Method

In the IAAO method, each infant was fed an amino acid based formula where each essential amino acid was present in excess except the test amino acid phenylalanine. The infant was randomly assigned to receive the test amino acid in an amount ranging

from deficient to excess (*i.e.*, each infant was given one specific intake level of the test amino acid for one test period). Lysine, labelled with a stable isotope, was used as the indicator amino acid for assessing phenylalanine requirement.

The IAAO method (Zello, 1993) is based on the concept that when the test amino acid intake is insufficient to meet the infant's requirements, protein synthesis will be limited and all of the amino acids will be oxidised, including the indicator amino acid. Oxidation of the indicator amino acid can be measured in expired air as $^{13}\text{CO}_2$.

Figure 1 shows an example of the graph plotted by the IAAO method for a test amino acid. As can be seen in Figure 1, as the dietary intake of the test amino acid (shown on the *x*-axis) increases, protein synthesis increases and the oxidation rate of the indicator amino acid (shown on the *y*-axis) decreases until the requirement of the test amino acid is met (indicated as the breakpoint). Once the requirement of the test amino acid is met, a further increase in its intake will have no further influence on the oxidation rate of the indicator amino acid. Thus the breakpoint determines the dietary requirement of the test amino acid in this setting.

IAAO Method – Protocol

24 hours before the study day, the infants consumed their test formula (including the specific intake level of the test amino acid being given for each particular infant) for adaptation, with the feeding regime conforming to that of the hospital. During the study day, the feeding regime was changed to hourly bolus feeding of the infant's test formula to ensure a metabolic steady state in feed condition. In order to quantify individual CO_2 production, the infants received a primed (14 $\mu\text{mol/kg}$) continuous (9 $\mu\text{mol/kg/h}$) infusion of [^{13}C]bicarbonate (sterile pyrogen free, 99% ^{13}C APE; Cambridge Isotopes, Woburn, MA) for 2.5 hours (Riedijk, 2005). Directly following the bicarbonate infusion, a primed (34 $\mu\text{mol/kg}$) continuous (40 $\mu\text{mol/kg/h}$) enteral infusion of [$1\text{-}^{13}\text{C}$]lysine 2HCl (99% ^{13}C APE; Cambridge Isotopes) was given for 4.5 hours. To minimise invasiveness the tracers were given enterally by means of a gastric tube. An excess of tyrosine (166 mg/kg/d) was used.

Breath samples were collected by means of the direct sampling method described by van der Schoor (2004). At baseline, two duplicate breath samples were obtained before tracer infusion. During the last 45 minutes of [^{13}C]bicarbonate infusion, and during the last hour of [$1\text{-}^{13}\text{C}$]lysine 2HCl infusion, duplicated samples were collected

every ten and fifteen minutes, respectively. Samples were stored at room temperature until monthly shipment to the Netherlands for analysis at the mass spectrometry laboratory of the Erasmus Medical Center, Rotterdam. Expired $^{13}\text{CO}_2$ enrichment was measured by isotope mass spectrometry (ABCA; Europe Scientific, van Loenen Instruments, Leiden, the Netherlands), and reported in units of atom percent excess (APE).

For each participant, the estimated body CO_2 production was calculated, as described previously (Riedijk, 2005). The rate of fractional $[1-^{13}\text{C}]$ lysine 2HCl oxidation was calculated using this equation:

$$\text{Fractional lysine oxidation (\%)} = [\text{IE}_{\text{LYS}} \times i_{\text{B}}] / [i_{\text{LYS}} \times \text{IE}_{\text{B}}] \times 100\%,$$

where IE_{LYS} is the excess ^{13}C isotopic enrichment in expired air during $[1-^{13}\text{C}]$ lysine 2HCl infusion (APE), i_{B} is the infusion rate of $[^{13}\text{C}]$ bicarbonate ($\mu\text{mol/kg/h}$), i_{LYS} is the infusion rate of $[1-^{13}\text{C}]$ lysine 2HCl ($\mu\text{mol/kg/h}$), and IE_{B} is the excess ^{13}C isotopic enrichment in expired air during $[^{13}\text{C}]$ bicarbonate infusion (van Goudoever, 1993).

Phenylalanine - Requirement

Using the method described above, the 16 infants as previously described were randomly assigned to phenylalanine intakes ranging from 5 to 177 mg/kg/d. There were 24 test intakes for the 16 preterm infants. The breakpoint for phenylalanine by the group of 16 infants (24 test intakes) was estimated to be $80 \text{ mg} \cdot \text{kg}^{-1} \cdot \text{d}^{-1}$.

These results are also illustrated graphically in Figure 2. In Figure 2, it is the oxidation rate of $[1-^{13}\text{C}]$ lysine 2HCl against dietary intake of the test amino acid (phenylalanine) that is plotted. Each point represents the result of a specific test intake of an individual infant who was fed an amino acid based formula where each essential amino acid was present in excess except phenylalanine, where phenylalanine was present in an amount ranging from deficient to excess. There were 24 test intakes for the 16 preterm infants.

Phenylalanine – Results and calculations

(1) Dietary requirement / recommended intake

The recommended dietary intake range for phenylalanine was then determined using
5 the following strategy.

First, the dietary requirement (breakpoint) of the IAAO results was estimated using a biphasic linear regression crossover model and was taken as the primary parameter.

The dietary requirement (breakpoint) for phenylalanine in preterm infants was estimated to be $80 \text{ mg} \cdot \text{kg}^{-1} \cdot \text{d}^{-1}$ as discussed above and also shown in Figure 2.

10 To ensure that nearly all individuals meet the amino acid requirements, a safe level of intake was defined. The safe level of protein intake proposed by the WHO (WHO/FAO/UNU, 2007) was used, defining the safe level of protein intake as 125% of the average protein requirement. In this instance, the safe level of amino acid intake was therefore calculated to be >125% of the primary parameter (breakpoint value)
15 obtained as described above, to reach the population safe requirement value.

An assumption was made that this primary parameter (breakpoint value) is higher than the requirement of protein bound amino acids based on the study by Metges (Metges, 2000) which showed > 20% higher first pass oxidation rate when free amino acids are ingested compared to protein bound amino acids. Therefore 20% of the
20 estimated requirement was subtracted from the population safe requirement value, which is believed to be conservative (*i.e.*, an overestimate rather than underestimate).

The net effect of the above two calculations is therefore that the breakpoint equals the recommended intake (measured in $\text{mg} \cdot \text{kg}^{-1} \cdot \text{d}^{-1}$).

**Therefore the recommended intake of phenylalanine in preterm infants was
25 established as $80 \text{ mg} \cdot \text{kg}^{-1} \cdot \text{d}^{-1}$.**

(2) Recommended intake levels in other units (*e.g.*, for preterm formulas)

The recommended intake measured in $80 \text{ mg} \cdot \text{kg}^{-1} \cdot \text{d}^{-1}$ was then converted to units of g (phenylalanine) / 100 g protein based on the ESPGHAN recommendations which
30 provide a guideline to provide 3.5 to 4.0 g protein per kg body weight per day for preterm infants weighing 1.0-1.8 kg. Thus, the recommended intake expressed in $\text{mg} \cdot \text{kg}^{-1} \cdot \text{d}^{-1}$ was divided separately by $3.5 \text{ g} \cdot \text{kg}^{-1} \cdot \text{d}^{-1}$ and by $4.0 \text{ g} \cdot \text{kg}^{-1} \cdot \text{d}^{-1}$ to reach a recommended dietary intake expressed in g (phenylalanine) / 100 g (protein).

Therefore the recommended intake of phenylalanine in preterm infants was determined to be 2.0-2.29 g phenylalanine / 100 g protein.

The recommended intake was also converted into units of g (protein) / 100 kcal (energy intake). This conversion also used the ESPGHAN guideline to provide 3.5 to 4.0 g protein per kg body weight per day for preterm infants weighing 1.0-1.8 kg, in combination with the recommended protein intake per day for preterm infants of 3.3 g (total protein) / 100 kcal. The calculations are indicated in Table 1 below, where it can be seen that the recommended intake level for phenylalanine in preterms in mg (phenylalanine) / 100 kcal was determined by multiplying the recommended intake expressed in mg (phenylalanine) / g (protein) by the energy intake levels of 3.2-3.6 g (protein) / 100 kcal.

Table 1: Calculations to determine recommended intake for phenylalanine in preterm infants expressed by way of energy intake

Breakpoint (mg/kg/d)	Protein level (g/kg/d)	Phe levels (mg/g protein)	Energy (g protein/ 100 kcal)	Phe level (mg/100 kcal)
80	3.5	22.9	3.2	22.9 x 3.2 = 73.14
80	3.5	22.9	3.6	22.9 x 3.6 = 82.29
80	4.0	20.0	3.2	20.0 x 3.2 = 64.00
80	4.0	20.0	3.6	20.0 x 3.6 = 72.00

Therefore the recommended intake of phenylalanine in preterm infants was also determined to be 64.00-82.29 mg phenylalanine / 100 kcal.

(3) Human milk fortifier levels

For consumption of fortified human milk, the same intake recommendations apply as those of preterm formulas (as calculated above). The recommended intake levels that are calculated above were also used in the determination of optimal phenylalanine levels in a human milk fortifier, taking into account the phenylalanine concentration in human milk.

Data on essential amino acid concentrations in preterm milk is sparse. Zhang and colleagues presented meta-analysis data for composition of transitional preterm milk (~day 6-20) and compared the composition of this milk to transitional term milk

(Zhang, 2013). However, from the same study it is clear that transitional (term) milk is an intermediate state in the lactation phase and varies compared to mature (term) milk (> day 20). In this publication, concentrations of phenylalanine were 79.1 and 63.8 mg/100 ml milk in preterm and term milk, respectively. However, the term milk concentrations at 2 months expression were much lower (46.0 mg/100 ml). Since preterm infants often receive donor milk, which in turn is most often mature term milk, the inventors used the term milk concentrations at 2 months lactation in determining the degree of fortification required to meet protein intake requirements (3.5-4.0 g/kg/d) without exceeding preterm requirements for phenylalanine (80 mg/kg/d).

Thus the calculations to determine the level of phenylalanine needed in a human milk fortifier (to supplement human milk) was determined based on human milk having the characteristics shown in Table 2.

Table 2: Characteristics of human milk (after 2 months lactation)

Human milk (2 months)	
Phe (mg/100 ml)	46.0
Protein level (Nx6.25)	1.31
Caloric content (kcal/100 ml)	65
Protein content (g/100 kcal)	2.02
Phe (mg/g protein)	35.11
Phe (mg/100 kcal)	70.77

First, the **protein gap** that needs to be filled with human milk fortifier (in order to meet protein requirements of preterm infants) was determined to be **1.185-1.585 g protein / 100 kcal HMF** based on a target protein of between 3.2-3.6 g (protein) / 100 kcal minus the protein content provided by the human milk as shown in Table 2 to be 2.02 g (protein) / 100 kcal.

Second, the **phenylalanine gap** that needs to be filled with human milk fortifier (in order to meet protein requirements of preterm infants) was determined by subtracting the phenylalanine content in the human milk (70.77 mg/100 kcal as shown in Table 2) from the recommended intake of phenylalanine in preterm infants of 64.00-82.29 mg phenylalanine / 100 kcal. This gives a range of **0-11.52 mg phenylalanine / 100 kcal in a human milk fortifier**. Based on total protein in the HMF of 1.185-1.585 g protein

/ 100 kcal HMF (as determined above), this also translates into **0-9.72 mg phenylalanine / g protein**.

These results provide a recommendation for a human milk fortifier to provide no additional phenylalanine beyond the phenylalanine level in human milk, or to provide a
5 very low level of phenylalanine (up to approximately 11.52 mg / 100 kcal).

Discussion

Recommendations directed at intake of specific essential amino acids in preterm infants currently do not exist. In the experiments described herein, the requirements for
10 phenylalanine in preterm infants was found to be lower than the current intake levels of preterm infants that are either fed existing preterm formulas or human milk fortified with a human milk fortifier. For example, in cow's milk-based preterm formulas, phenylalanine levels have been reported to vary between 3.54-4.53 g (phenylalanine) / 100 g protein (Picaud, 2001; Moro, 1999; Darling, 1999; Szajewska, 2001) or 91.64-
15 118.25 mg (phenylalanine) / 100 kcal (Picaud, 2001; Moro, 1999; Darling, 1999; Szajewska, 2001).

Preterm infants require high levels of protein (considerably higher than term infants), and therefore these results suggesting a lower level of one of the essential amino acids were unexpected. Without wishing to be bound by theory, the inventors
20 postulate that these results may indicate that it is the relative concentration of phenylalanine to the concentrations of the other amino acids (and not the total protein levels) that need to be changed in existing preterm formulations, particularly preterm formulas and human milk fortifiers.

For instance, phenylalanine and other large neutral amino acids compete for
25 transport across the blood-brain barrier via the L-type amino acid carrier, as well as at the gut-blood barrier (Pietz, 1999). Elevated plasma phenylalanine concentrations thus impair brain uptake of other large neutral amino acids, and is seen most acutely in patients suffering from phenylketonutria (PKU). Direct effects of elevated phenylalanine concentrations and depleted large neutral amino acid concentrations in
30 the brain are probably major causes for disturbed brain development and function in PKU. One of the therapeutic strategies in PKU is supplementing large neutral amino acids to the patients, based on the rationale that this will favourably increase the transport of large neutral amino acids at the blood-brain barrier and also at the gut-

blood barrier, resulting in lower phenylalanine concentrations in the brain and plasma. The insights from the present invention, namely that preterm infants require less phenylalanine than is currently provided in preterm formulations, particularly preterm formulas and human milk fortifiers, and thus the proposition that phenylalanine

5 concentrations should be reduced relative to other amino acids in preterm formulations, mean that the large neutral amino acids involved in protein accretion will have a better bioavailability due to less transporter competition. As a result, the lower ratio of phenylalanine to other amino acids, especially the large neutral amino acids, may promote, assist or achieve balanced growth or development of a preterm infant, and in

10 particular the growth or development of the brain of a preterm infant.

REFERENCES

1. Agostoni, C., Buonocore, G., Carnielli, V.P., De Curtis, M., Darmaun, D., Decsi, T., Domellof, M., Embleton, N.D., Fusch, C., Genzel-Boroviczeny, O., Goulet, O., Kalhan, S.C., Kolacek, S., Koletzko, B., Lapillonne, A., Mihatsch, W., Moreno, L., Neu, J., Poindexter, B., Puntis, J., Putet, G., Rigo, J., Riskin, A., Salle, B., Sauer, P., Shamir, R., Szajewska, H., Thureen, P., Turck, D., Van Goudoever, J.B. and Ziegler, E.E. "Enteral Nutrient Supply for Preterm Infants: Commentary from the European Society of Paediatric Gastroenterology, Hepatology and Nutrition Committee on Nutrition." *J. Pediatr. Gastroenterol. Nutr.*, 2010: 50(1); 85-91.
- 10 2. Darling, P.B. *et al.*, "Threonine kinetics in preterm infants fed their mothers' milk or formula with various ratios of whey to casein" *Am J Clin Nutr* 1999 Jan: 69(1); 105-114.
3. Klein, C.J. "Nutrient Requirements for Preterm Infant Formulas." *J. Nutr.* 2002: 132(6 Suppl 1); 1395S-1577S.
- 15 4. Metges, C.C. *et al.*, "Kinetics of L-[1-(13)C]leucine when ingested with free amino acids, unlabeled or intrinsically labeled casein" *Am J Physiol Endocrinol Metab* 2000: 278(6); E1000-9.
5. Moro G., Minoli I., Boehm G., Georgi G., Jelinek J., Sawatzki G., "Postprandial plasma amino acids in preterm infants: influence of the protein source." *Acta Paediatr* 1999: 88; 885-889.
- 20 6. Picaud J-C., Rigo J., Normand S., Lapillonne A., Reygrobellet B., Claris O., Salle B. L., "Nutritional Efficacy of Preterm Formula With a Partially Hydrolyzed Protein Source: A Randomized Pilot Study" *Journal of Pediatric Gastroenterology and Nutrition* 2001 May: 32; 555-561.
- 25 7. Riedijk M.A., Voortman G., van Goudoever J.B., "Use of [13C]bicarbonate for metabolic studies in preterm infants: intragastric versus intravenous administration." *Pediatr Res* 2005: 58; 861-4.
8. Szajewska H., Albrecht P., Stoinska B., Prochowska A., Gawecka A., Laskowska-Klita T., "Extensive and Partial Protein Hydrolysate Preterm Formulas: The Effect on Growth Rate, Protein Metabolism Indices, and Plasma Amino Acid Concentrations" *Journal of Pediatric Gastroenterology and Nutrition* 2001 March: 30 32; 303-309.

9. van der Schoor, S.R. *et al.*, "Validation of the direct nasopharyngeal sampling method for collection of expired air in preterm neonates." *Pediatr Res* 2004; 55(1); 50-54.
10. van Goudoever J.B., Sulkers E.J., Chapman T.E., *et al.* "Glucose kinetics and glucoregulatory hormone levels in ventilated preterm infants on the first day of life." *Pediatr Res* 1993; 33; 583-9.
11. WHO MULTICENTRE GROWTH REFERENCE STUDY GROUP "WHO Child Growth Standards based on length/height, weight and age" *Acta Paediatrica* 2006; Suppl 450; 76-85.
- 10 12. WHO/FAO/UNU, Protein and amino acid requirements in human nutrition. WHO Technical Report Series, 2007(935): p. 1-265.
13. Zello, G.A. *et al.*, "Dietary lysine requirement of young adult males determined by oxidation of l-[1-13C]phenylalanine" *Am J Physiol Endocrinol Metab* 1993; 264; E677-E685.
- 15 14. Zhang Z., Adelman A.S., Rai D., Boettcher J., Lonnerdal B., "Amino Acid Profiles in Term and Preterm Human Milk through Lactation: A Systematic Review" *Nutrients* 2013 Nov 26; 5(23):4800-21.

In this document and in its claims, the verb "to comprise" and its conjugations is used in its non-limiting sense to mean that items following the word are included, but items not specifically mentioned are not excluded. In addition, reference to an element by the indefinite article "a" or "an" does not exclude the possibility that more than one of the element is present, unless the context clearly requires that there be one and only one of the elements. The indefinite article "a" or "an" thus usually means "at least one".

Each of the applications and patents mentioned in this document, and each document cited or referenced in each of the above applications and patents, including during the prosecution of each of the applications and patents ("application cited documents") and any manufacturer's instructions or catalogues for any products cited or mentioned in each of the applications and patents and in any of the application cited documents, are hereby incorporated herein by reference. Furthermore, all documents cited in this text, and all documents cited or referenced in documents cited in this text, and any manufacturer's instructions or catalogues for any products cited or mentioned in this text, are hereby incorporated herein by reference.

Various modifications and variations of the described methods and system of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with specific preferred embodiments, it should be understood that the invention as
5 claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention which are obvious to those skilled in molecular biology or related fields are intended to be within the scope of the claims.

CLAIMS

1. A preterm formulation comprising a proteinaceous composition, wherein the preterm formulation:
 - 5 a) comprises 2.0-2.29 g phenylalanine per 100 g protein;
 - b) comprises 64.00-82.29 mg phenylalanine per 100 kcal; and/or
 - c) provides, or is formulated to provide phenylalanine in an amount of 80-96 mg / kg body weight per day.
- 10 2. A preterm formulation according to claim 1, comprising a preterm formula.
3. A preterm formulation according to claim 1, comprising human milk and a human milk fortifier.
- 15 4. A preterm formulation comprising a human milk fortifier comprising a proteinaceous composition, wherein the human milk fortifier:
 - a) comprises 0-11.52 mg phenylalanine per 100 kcal;
 - b) comprises 0-9.72 mg phenylalanine per g protein; and/or
 - c) provides, or is formulated to provide phenylalanine in an amount of 80-96
20 mg per kg body weight per day.
5. Use of a composition in the manufacture of a preterm formulation, wherein the preterm formulation is a preterm formulation according to any one of claims 1-4.
- 25 6. Use of a composition in the manufacture of a preterm formulation for promoting, assisting or achieving balanced growth or development in a preterm infant and/or for preventing or reducing the risk of unbalanced growth or development in a preterm infant, wherein the preterm formulation is a preterm formulation according to any one of claims 1-4.
- 30 7. Use of a composition in the manufacture of a preterm formulation for promoting, assisting or achieving balanced growth or development of the brain of a preterm

infant and/or the cognitive function of a preterm infant, wherein the preterm formulation is a preterm formulation according to any one of claims 1-4.

8. Use of a composition in the manufacture of a preterm formulation for promoting, assisting or achieving balanced growth or development of the body of a preterm infant and/or the preterm infant's body composition, wherein the preterm formulation is a formula according to any one of claims 1-4.
9. Method for providing nutrition to a preterm infant; and/or for promoting, assisting or achieving balanced growth or development in a preterm infant and/or for preventing or reducing the risk of unbalanced growth or development in a preterm infant, said method comprising administering a preterm formulation according to any one of claims 1-4 to said preterm infant.
10. Method of claim 9, for promoting, assisting or achieving balanced growth or development of the brain of the infant and/or the cognitive function of the preterm infant.
11. Method of claim 9, for promoting, assisting or achieving balanced growth or development of the body of a preterm infant and/or the preterm infant's body composition.
12. A method for the manufacture of a preterm formulation, the method comprising admixing:
 - i. human breast milk; and
 - ii. a human milk fortifier composition comprising a proteinaceous composition, wherein the human milk fortifier composition:
 - a) comprises 0-9.72 phenylalanine per 100 g protein;
 - b) comprises 0-11.52 mg phenylalanine per 100 kcal; and/or
 - c) provides, or is formulated to provide phenylalanine in an amount of 80-96 mg per kg body weight per day.

13. A proteinaceous composition comprising 2.0-2.29 g phenylalanine per 100 g protein.
14. Preterm formulation for use in providing nutrition to a preterm infant; and/or for
5 use in promoting, assisting or achieving balanced growth or development in a preterm infant and/or for use in preventing or reducing the risk of unbalanced growth or development in a preterm infant, comprising administering a preterm formulation according to any one of claims 1-4 to said preterm infant.
- 10 15. Preterm formulation for use according to claim 14, for use in promoting, assisting or achieving balanced growth or development of the brain of the infant and/or the cognitive function of the preterm infant.
- 15 16. Preterm formulation for use according to claim 14, for use in promoting, assisting or achieving balanced growth or development of the body of a preterm infant and/or the preterm infant's body composition.

Fig. 1





Fig. 2



INTERNATIONAL SEARCH REPORT

International application No
PCT/NL2014/050315

A. CLASSIFICATION OF SUBJECT MATTER
INV. A23L1/305 A23L1/29
ADD.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
A23L

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EPO-Internal, WPI Data, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP 0 418 593 A2 (MILUPA AG [DE] MILUPA GMBH & CO KG [DE]) 27 March 1991 (1991-03-27) the whole document	1-3, 5-11, 14-16
A	----- WO 2011/119023 A1 (NUTRICIA NV [NL]; VAN GOUDOEVER JOHANNES BERNARD [NL]; VAN DER BEEK EL) 29 September 2011 (2011-09-29) the whole document	1-3, 5-11, 14-16
A	----- WO 2010/112430 A1 (NESTEC SA [CH]; APRIKIAN OLIVIER [US]; BLANCHER FLORENCE [CH]; MACE CA) 7 October 2010 (2010-10-07) example 1 ----- -/--	1-3, 5-11, 14-16



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

25 March 2015

Date of mailing of the international search report

24/04/2015

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040,
Fax: (+31-70) 340-3016

Authorized officer

Fischer, J

INTERNATIONAL SEARCH REPORT

International application No
PCT/NL2014/050315

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP 1 932 437 A1 (NESTEC SA [CH]) 18 June 2008 (2008-06-18) the whole document	1-3, 5-11, 14-16
A	----- BALLHAUSEN ET AL.: "Born at 27 weeks of gestation with classical PKU: challenges of dietetic management in a very preterm infant", PEDIATRIC REPORTS, vol. 3:e26, 22 September 2011 (2011-09-22) , pages 103-107, XP002735149, the whole document	1-3, 5-11, 14-16
X	----- WO 2007/121807 A1 (FRESENIUS KABI DE GMBH [DE]; BRAND ORTRUD [DE]; ERBE THORSTEN [DE]; AC) 1 November 2007 (2007-11-01) example 1	1,2,4-6, 8,9,11, 14-16
A	----- DATABASE CAPLUS [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 12 May 1984 (1984-05-12), Guettler et al.: "Serum tyrosine within the first hour after an oral lod of phenylalanine", XP002737745, retrieved from stn Database accession no. 1978:488340 abstract -----	1-12, 14-16

INTERNATIONAL SEARCH REPORT

International application No.
PCT/NL2014/050315

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of Item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fees, this Authority did not invite payment of additional fees.
3. ☒ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
1-12, 14-16(all partially)
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- ☐ The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- ☒ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 1-3, 5-11, 14-16(all partially)

A preterm formulation comprising a proteinaceous composition, wherein the preterm formulation: a) comprises 2.0-2.29 g phenylalanine per 100 g protein; b) comprises 64.00-82.29 mg phenylalanine per 100 kcal; and c) provides, or is formulated to provide phenylalanine in an amount of 80-96 mg/kg body weight per day and uses

2. claims: 1-12, 14-16(all partially)

A preterm formulation comprising a proteinaceous composition, wherein the preterm formulation: c) provides, or is formulated to provide phenylalanine in an amount of 80-96 mg/kg body weight per day, method of manufacture and uses,

3. claims: 4-11, 14-16(all partially)

A preterm formulation comprising a human milk fortifier comprising a proteinaceous composition, wherein the human milk fortifier comprises a) 0-11.52 mg phenylalanine per 100 kcal; b) 0-9.72 mg phenylalanine per g protein; and c) provides, or is formulated to provide phenylalanine in an amount of 80- 96mg per kg body weight per day, uses and method of manufacture.

4. claim: 12(partially)

A method for the manufacture of a preterm formulation, the method comprising admixing: human breast milk; and a human milk fortifier composition comprising a proteinaceous composition, wherein the human milk fortifier composition: a) comprises 0-9.72 phenylalanine per 100 g protein; b) comprises 0-11.52 mg phenylalanine per 100 kcal; and c) provides, or is formulated to provide phenylalanine in an amount of 80-96 mg per kg body weight per day.

5. claim: 13

A proteinaceous composition comprising 2.0-2.29 g phenylalanine per 100 g protein.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/NL2014/050315

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0418593	A2	27-03-1991	AT 96621 T 15-11-1993
		DD 297304 A5 09-01-1992	
		DE 59003330 D1 09-12-1993	
		DK 0418593 T3 13-12-1993	
		EP 0418593 A2 27-03-1991	
		ES 2062231 T3 16-12-1994	
		GR 3026131 T3 29-05-1998	
		PT 95114 A 18-04-1991	
		TR 24775 A 01-05-1992	

WO 2011119023	A1	29-09-2011	CN 102892309 A 23-01-2013
		EP 2552242 A1 06-02-2013	
		RU 2012145528 A 20-05-2014	
		US 2013079276 A1 28-03-2013	
		WO 2011119023 A1 29-09-2011	
		WO 2011119033 A1 29-09-2011	

WO 2010112430	A1	07-10-2010	AU 2010230283 A1 13-10-2011
		CA 2755860 A1 07-10-2010	
		CN 102378632 A 14-03-2012	
		EP 2413952 A1 08-02-2012	
		RU 2011144581 A 10-05-2013	
		SG 174355 A1 28-10-2011	
		TW 201039754 A 16-11-2010	
		US 2012021977 A1 26-01-2012	
		WO 2010112430 A1 07-10-2010	

EP 1932437	A1	18-06-2008	AT 543395 T 15-02-2012
		AU 2007331578 A1 19-06-2008	
		BR PI0721087 A2 25-02-2014	
		CA 2671988 A1 19-06-2008	
		CN 101573049 A 04-11-2009	
		EP 1932437 A1 18-06-2008	
		EP 2096941 A1 09-09-2009	
		ES 2379737 T3 03-05-2012	
		PL 2096941 T3 31-07-2012	
		PT 2096941 E 11-04-2012	
		RU 2009127103 A 20-01-2011	
		TW 200845917 A 01-12-2008	
		UA 96781 C2 12-12-2011	
		US 2010092610 A1 15-04-2010	
		WO 2008071667 A1 19-06-2008	
		ZA 200904918 A 29-09-2010	

WO 2007121807	A1	01-11-2007	AR 060555 A1 25-06-2008
		AU 2007241469 A1 01-11-2007	
		BR PI0710298 A2 09-08-2011	
		CA 2647087 A1 01-11-2007	
		CN 101420933 A 29-04-2009	
		DE 102006018293 A1 25-10-2007	
		EA 200870451 A1 28-04-2009	
		EP 2007348 A1 31-12-2008	
		JP 2009534323 A 24-09-2009	
		KR 20090010050 A 28-01-2009	
		TW 1429405 B 11-03-2014	
		US 2009203626 A1 13-08-2009	
		WO 2007121807 A1 01-11-2007	
		ZA 200807860 A 26-08-2009	

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/NL2014/050315

Patent document cited in search report	Publication date	Patent family member(s)	Publication date